| Nov 15 |
Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02
|
| Nov 14 |
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Nov 13 |
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
|
| Nov 13 |
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
|
| Oct 31 |
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
|
| Oct 12 |
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
|
| Sep 23 |
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
|
| Aug 19 |
Aileron Therapeutics to Present at the 8th Annual IPF Summit
|
| Aug 15 |
Aileron Therapeutics GAAP EPS of -$0.45
|
| Aug 14 |
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
|
